Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease

References

• Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of emolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37–47.
   PubMed Web of Science ®Google Scholar
• Mansi IA, Rosner F. Myocardial infarction in sickle cell disease. J Natl Med Assoc. 2002;94:448–52.
   PubMed Web of Science ®Google Scholar
• Westerman MP. Hypocholesterolaemia and anaemia. Br J Haematol. 1975;31:87–94.
   PubMed Web of Science ®Google Scholar
• Papanastasiou DA, Siorokou T, Haliotis FA. β-thalassaemia and factors affecting the metabolism of lipids of lipids and lipoproteins. Haematologia 1996;27:143–53.
   PubMedGoogle Scholar
• Hartman C, Tamary H, Tamir A, Shabad E, Levine C, Koren A, et al. Hypocholesterolemia in children and adolescents with β-thalassemia intermedia. J Pediatr. 2002;141:543–7
   PubMed Web of Science ®Google Scholar
• VanderJagt DJ, Shores J, Okorodudu A, Okolo SN, Glew RH. Hypocholesterolemia in Nigerian children with sickle cell disease. J Trop Pediatr. 2002;48:156–61.
   PubMed Web of Science ®Google Scholar
• Johnsson R, Saris NE. Plasma and erythrocyte lipids in hereditary spherocytosis. Clin Chim Acta 1981;114:263–8.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Suto Y, Sato H, Arai K, Waga S, Kitazawa J, et al. Low serum lipids suggest severe bone marrow failure in children with aplastic anemia. Pediatr Int. 2000;42:613–9.
   PubMed Web of Science ®Google Scholar
• Zorca S, Freeman L, Hildesheim M, Allen D, Remaley AT, Taylor JG 6th, et al. Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. Br J Haematol. 2010;149:436–45.
   PubMed Web of Science ®Google Scholar
• Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest. 2000;106:337–8.
   PubMed Web of Science ®Google Scholar
• Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation 2004;11:129–51.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Brittain JE, Jones SK, May R, Delaney J, Strayhorn D, et al. Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease. Br J Haematol. 2011;152:485–91.
   PubMed Web of Science ®Google Scholar
• Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on western diet. Circ Res. 2005;97:1190–7.
   PubMed Web of Science ®Google Scholar
• Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, et al. Pain in sickle cell disease. N Engl J Med. 1991;325:11–6.
   PubMed Web of Science ®Google Scholar
• Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et al. National Acute Chest Syndrome Study Group. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 2000;342:1855–65.
   PubMed Web of Science ®Google Scholar
• Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288–94.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008;93:20–6.
   PubMed Web of Science ®Google Scholar
• McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001;104:2797–802.
   PubMed Web of Science ®Google Scholar
• Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med. 2000;15:395–9.
   PubMed Web of Science ®Google Scholar
• Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7:1–26.
   Web of Science ®Google Scholar
• Shalev H, Kapelushnik J, Moser A, Knobler H, Tamary H. Hypocholesterolemia in chronic anemias with increased erythropoietic activity. Am J Hematol. 2007;82:199–202.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Barnett JP. Metabolic and health complications of obesity. Dis Mon. 1990;36:641–731.
   PubMed Web of Science ®Google Scholar
• Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart disease. Lancet 1975;1:16–9.
   PubMed Web of Science ®Google Scholar
• Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 1996;37:2473–91.
   PubMed Web of Science ®Google Scholar
• Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol. 1998;82:13Q–21Q.
   PubMed Web of Science ®Google Scholar
• Navab M, Hama-Levy SY, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005–19.
   PubMed Web of Science ®Google Scholar
• Castellani L, Navab M, Hama SY, Hedrick CC, Lusis AJ. Overexpression of apolipoprotein AII in mice converts high density lipoprotein to a pro-inflammatory particle. J Clin Invest. 1997;100:464–74.
   PubMed Web of Science ®Google Scholar
• Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, et al. Role of group II secretory phospholipase A2 in atherosclerosis. 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol. 1999;19:1291–8.
   PubMed Web of Science ®Google Scholar
• Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998;394:284–7.
   PubMed Web of Science ®Google Scholar
• Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–67.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46–57.
   PubMed Web of Science ®Google Scholar
• Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487–94.
   PubMed Web of Science ®Google Scholar
• McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006;54:2541–9.
   PubMed Web of Science ®Google Scholar
• Sorci-Thomas MG, Thomas MJ. High density lipoprotein biogenesis, cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol. 2012;32:2561–5.
   PubMed Web of Science ®Google Scholar
• Aken'ova YA, Olasode BJ, Ogunbiyi JO, Thomas JO. Hepatobiliary changes in Nigerians with sickle cell anaemia. Ann Trop Med Parasitol. 1993;87:603–6.
   PubMed Web of Science ®Google Scholar
• Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, et al. L-4f, an apolipoprotein a-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003;107:2337–41.
   PubMed Web of Science ®Google Scholar
• Alkhouri N, Tamimi TA, Yerian L, Lopez R, Zein NN, Feldstein AE. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig Dis Sci. 2010;55:2644–50.
   PubMed Web of Science ®Google Scholar
• Gustavsson C, Agardh CD, Zetterqvist AV, Nilsson J, Agardh E, Gomez MF. Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia. PLoS ONE 5:e12699.
   PubMed Web of Science ®Google Scholar
• Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255–64.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Am Soc Hematol Educ Program 2007;91–6.
   PubMedGoogle Scholar
• Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS ONE 7:e29786.
   PubMed Web of Science ®Google Scholar
• Brand K, Banka CL, Mackman N, Terkeltaub RA, Fan ST, Curtiss LK. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb. 1994;14:790–7.
   PubMedGoogle Scholar
• Meisel SR, Xu XP, Edgington TS, Cercek B, Ong J, Kaul S, et al. Dose-dependent modulation of tissue factor protein and procoagulant activity in human monocyte-derived macrophages by oxidized low density lipoprotein. J Atheroscler Thromb. 2011;18:596–603.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886–95.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006;134:109–15.
   PubMed Web of Science ®Google Scholar